June 2020 - Linnaeus

Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA in Patients with Advanced Cancer

Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA in Patients with Advanced Cancer

By wpteam|2020-06-23T14:26:53+00:00June 23rd, 2020|

Linnaeus announced today announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of its lead investigational product candidate LNS8801, and Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab) in patients with selected advanced solid tumors. Haddonfield NJ, June 23, 2020--Linnaeus Therapeutics, Inc. (Linnaeus), a privately [...]

Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti–PD-1/L1 Therapy

By wpteam|2020-06-22T14:22:50+00:00June 22nd, 2020|

Linnaeus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on or after anti–programmed cell death receptor or ligand (anti–PD-1/L1) therapy. Haddonfield NJ, June 18, [...]

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology

By wpteam|2020-06-12T15:15:34+00:00June 10th, 2020|

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology Haddonfield NJ, June 10, 2020 -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that its [...]